APONTIS PHARMA AG Announces Merger Squeeze-out at EUR 10.40

APONTIS PHARMA AG disclosed that Zentiva AG has requested the transfer of shares from minority shareholders with a cash compensation set at EUR 10.40 per share. Zentiva AG, holding approximately 93.83% of share capital after accounting for treasury shares, has proposed this compensation as part of a merger squeeze-out.

The proposed merger agreement will be concluded and notarized shortly. The final decision is scheduled for APONTIS PHARMA's annual general meeting on 29 July 2025. The merger's effectiveness hinges on the meeting's approval and subsequent registration in both companies' commercial registers.

This strategic move consolidates Zentiva AG's control over APONTIS PHARMA AG, aligning with their broader corporate goals.